Akila Karanja
Family · South Bend, INNPI 1447506688
Payments from drug & device makers
Across 160 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$300
- Insulet Corporation$242
- Lilly USA, LLC$205
- Dexcom, Inc.$162
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$160
- plus $740 from 17 others
What the payments were for
- Food & beverage$2,78196%
- Other$1154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $1,087 |
| Novartis | 19 | $300 |
| Insulet Corporation | 7 | $242 |
| Lilly USA, LLC | 14 | $205 |
| Dexcom, Inc. | 9 | $162 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $160 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $125 |
| Welch Allyn | 1 | $86 |
| Novo Nordisk | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Pfizer | 3 | $47 |
| Exact Sciences | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| AstraZeneca | 3 | $45 |
| GSK | 2 | $35 |
| VBI Vaccine (delaware) Inc. | 1 | $30 |
| Merck | 2 | $30 |
| Baxter Healthcare | 1 | $29 |
| Abbott | 1 | $24 |
| Gilead | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
How this compares
$2,896 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 27 | $36,369 |
| TrulicityDulaglutide | 28 | $31,388 |
| JanuviaSitagliptin Phosphate | 11 | $16,991 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $7,058 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,720 |
| Gabapentin | 67 | $1,097 |
| Amlodipine Besylate | 211 | $946 |
| Chlorthalidone | 57 | $676 |
| Atorvastatin Calcium | 105 | $633 |
| Levothyroxine Sodium | 69 | $541 |
| Metformin Hcl | 83 | $458 |
| Lisinopril | 114 | $376 |
| Enalapril Maleate | 26 | $315 |
| Hydroxyzine Hcl | 24 | $300 |
| Hydralazine Hcl | 19 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $205 | $31,38828 claims |
| MerckJanuvia | $30 | $16,99111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in South Bend
- Caitlin VlaeminckSouth Bend$14K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.